Survival analysis in patients with newly diagnosed glioblastoma using pre-and postradiotherapy MR spectroscopic imaging

Neuro-Oncology

Volumn 15, Issue 5, 2013, Pages 607-617

  Li, Yan ^a   Lupo, Janine M ^a   Parvataneni, Rupa ^a   Lamborn, Kathleen R ^a   Cha, Soonmee ^a   Chang, Susan M ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

glioblastoma; magnetic resonance spectroscopic imaging; survival

Indexed keywords

CHOLINE; ERLOTINIB; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; TEMOZOLOMIDE; TIPIFARNIB;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTON NUCLEAR MAGNETIC RESONANCE; THREE DIMENSIONAL IMAGING;

BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84877100892     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos334     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
3. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113: 405-410.
4. Wasserfallen JB, Ostermann S, Leyvraz S, Stupp R. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol. 2005; 7: 189-195.
5. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010; 28: 1963-1972.
6. Martinez-Bisbal MC, Celda B. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging. 2009; 53: 618-630.
7. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993; 13: 981-989.
8. Galanaud D, Chinot O, Nicoli F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from lowgrade glioma. J Neurosurg. 2003; 98: 269-276.
9. Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging. 2002; 16: 229-237.
10. Star-Lack J, Spielman D, Adalsteinsson E, et al. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson. 1998; 133: 243-254.
11. Park I, Chen AP, Zierhut ML, et al. Implementation of 3T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for glioma patients. Ann Biomed Eng. 2011; 39: 193-204.
12. Catalaa I, Henry R, Dillon WP, et al. Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed. 2006; 19: 463-475.
13. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003; 24: 1989-1998.
14. Chang SM, Nelson S, Vandenberg S, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol. 2009; 92: 401-415.
15. Nelson SJ, Graves E, Pirzkall A, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging. 2002; 16: 464-476.
16. Park I, Tamai G, Lee MC, et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys. 2007; 69: 381-389.
17. Laprie A. [Proton magnetic resonance spectroscopic imaging and other types of metabolic imaging for radiotherapy planning in adult and pediatric high-grade gliomas]. Cancer Radiother. 2009; 13: 556-561.
18. Kuznetsov YE, Caramanos Z, Antel SB, et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery. 2003; 53: 565-574. discussion 574-566.
19. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004; 19: 546-554.
20. Crawford FW, Khayal IS, McGue C, et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol. 2009; 91: 337-351.
21. Saraswathy S, Crawford FW, Lamborn KR, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2009; 91: 69-81.
22. Quon H, Brunet B, Alexander A, et al. Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. Anticancer Res. 2011; 31: 3559-3565.
23. Li Y, Lupo JM, Polley MY, et al. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2011; 13: 546-557.
24. McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging. 2001; 13: 167-177.
25. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med. 2000; 43: 23-33.
26. Li Y, Osorio JA, Ozturk-Isik E, et al. Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T. Magn Reson Imaging. 2006; 24: 1295-1302.
27. Li X, Vigneron DB, Cha S, et al. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. AJNR Am J Neuroradiol. 2005; 26: 760-769.
28. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 2001; 46: 228-239.
29. Nelson SJ, Nalbandian AB, Proctor E, Vigneron DB. Registration of images from sequential MR studies of the brain. J Magn Reson Imaging. 1994; 4: 877-883.
30. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm. IEEE Trans Med Imaging. 2001; 20: 45-57.
31. Park I, Elkhaled A, Kadambi A, et al. Finding of early prognostic marker from 3D 1H-MRSI and diffusion tensor imaging for newly-diagnosed GBM patients receiving radiation, temozolomide and PKC Inhibitor. Paper presented at: International Society for Magnetic Resonance in Medicine annual meeting; May 2010. Stockholm, Sweden.
32. Sundgren PC, Nagesh V, Elias A, et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury - an MR spectroscopy study. J Magn Reson Imaging. 2009; 29: 291-297.
33. Esteve F, Rubin C, Grand S, Kolodie H, Le Bas JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys. 1998; 40: 279-286.
34. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002; 97: 794-802.
35. Polley MY, Lamborn KR, Chang SM, et al. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010; 12: 274-282.
36. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol. 1997; 32: 253-265.
37. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 1997; 57: 3860-3864.
38. Dringen R, Verleysdonk S, Hamprecht B, et al. Metabolism of glycine in primary astroglial cells: synthesis of creatine, serine, and glutathione. J Neurochem. 1998; 70: 835-840.
39. Londono A, Castillo M, Armao D, Kwock L, Suzuki K, Unusual MR. Spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels. AJNR Am J Neuroradiol. 2003; 24: 942-945.
40. Hattingen E, Raab P, Franz K, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. 2008; 50: 759-767.
41. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE. Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol Scand. 1998; 97: 52-62.
42. Franceschi E, Tosoni A, Bartolini S, et al. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther. 2009; 9: 613-619.
43. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs. 2009; 23: 289-304.